Renoprotective effects of antihypertensive drugs. Part I;Renoprotektion durch antihypertensiva: Teil I

Medizinische Klinik

Volumn 97, Issue 9, 2002, Pages 541-546

  Stein, Günter ^a   Fünfstück, Reinhard ^b   Sperschneider, Heide ^a   Ritz, Eberhard ^c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Sophien und Hufeland Klinikum Weimar   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiotensin II blocking agents; Antihypertensive treatment; Chronic renal failure; Diabetic nephropathy; Hypertension; Progression; Proteinuria

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; RAMIPRIL; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR;

ANTIHYPERTENSIVE THERAPY; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; HUMAN; HYPERTENSION; PROTEINURIA; REVIEW; RISK FACTOR; RISK MANAGEMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RISK FACTORS;

EID: 84897454303     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-002-1192-2     Document Type: Review

References (62)

1. Agodoa LY, Apple L, Bakris GL, et al., for the AASK Study Group. Effect of Ramipril vs Amlodipine on renal outcomes in renal hypertensive nephrosclerosis. A randomized controlled trial. JAMA 2001;285:2719-28.
2. Amann K, Simonaviciene A, Medwedewa T, et al. Blood pressure-independend additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage. J Am Soc Nephrol 2001;12:2572-84.
3. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002;25:Suppl 1:S71-3.
4. American Diabetes Association. Diabetic nephropathy. Diabetes Care 2002;25:Suppl 1:S85-9.
5. Bakris GL, Copley JB, Vicknaer N, Sadler R, Leurgrans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-50.
6. Bakris GI, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997;29:744-50.
7. Bakris GI, Weir MR, De Quattro V, McMahon FG. Effects of an ACE-inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-9.
8. Brenner BM, Cooper ME, De Zeeuw D, et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345: 861-9.
9. Brunner FP, Thiel G, Hermle M, Bock HA, Mihatsch MJ. Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 1998;36:969-77.
10. Crepaldi G, Carta Q, Deferrari G, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998;21:104-10.
11. De Jong PE, Navig G, de Zeeuw G. Renal protective therapy: titration against urinary protein excretion. Lancet 1999;354:352-3.
12. Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuna associated with diabetes mellitus. Ann Intern Med 1990;113:987-8.
13. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;138:645-52.
14. Ferrari P, Marti HP, Pfister M, Frey FJ. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002; 20:125-30
15. Fogo AB. The role of angiotensin-II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Indepth review. Am J Kidney Dis 2000;35:179-88.
16. Fogo AB. Progression and potential regression of glomerulosclerosis. Nephrology forum. Kidney Int 2001;59:804-19.
17. Gerstein HC, Bosch J, Pogue J, et al. Rational and design of a large study to evaluate the renal and cardiovascular effects of an ACE-inhibitor and vitamin E in high-risk patients with diabetes: the MICRO-HOPE Study. Diabetes Care 1996;19:1225-8.
18. Gerstein HC, Mann JFE, Yi Q, et al., for the HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001;286:421-6.
19. Guasch A, Parham M, Zayas CF, Campbell O, Zerue CN, Macon E. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin dependent diabetes mellitus and nephropathy. J Am Soc Nephrol 1997;8:793-8.
20. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001;345:910-2.
21. Jafar TH, Schmid CHH, Landa M, et al. Angiotenin-converting enzyme inhibitors and progression of non-diabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.
22. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999;33:1004-10.
23. Klahr S, Levey ASS, Beck GJ, et al., for the MDRD Study Group. The effect of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl Med 1994;330:877-84.
24. Klahr S, Breyer JA, Beck GJ, et al. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol 1995;6:2037-47.
25. Kloke HJ, Branten AJ, Thuysmans F, Wetzels JF. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int 1998;53:1559-73.
26. Koshy S, Bakris GL. Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther 2000;14:295-305.
27. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, and the Collaborative Study Group. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
28. Lewis EJ, Hunsicker LG, Clark WR, et al. Renoprotective effect of the angiotenin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
29. Lichtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity, by enalapril in patients with chronic renal failure. N Engl J Med 1999;340:321-8.
30. Loutzenhiser R, Epstein M. Calcium antagonists and the kidney. Am J Hypertens 1989;2:154-61.
31. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insuffiziency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-45.
32. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminutia. Br Med J 1991;302:210-6.
33. Meyer FP. Wird die Euphorie vom Realismus eingeholt? BDI Aktuell 2002;2:24-7
34. Mitch WE, Walser M, Buffington GA, et al. A simple method of estimating progression of chronic renal failure. Lancet 1976;2:1326-8.
35. Mogensen CE, Neldam ST, Tikkanen I, et al., for the CALM Study Group. Randomized controlled trial of dual blockade of renin-angiotensin-system in patients with hypertension, microalbuminuria, and non-insulin-dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000;321: 1440-4.
36. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982;285:685-8.
37. Navie A, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999;354:352-3.
38. Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998;9:224-30.
39. Parving HH, Andersen A, Smidt SM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-8.
40. Parving HH, Lehnert A. Bröchner-Mortensen J, et al., for the IRMA Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
41. Parving HH, Hommel E, Jenson BR, Hansen HP. Longterm beneficial effect of ACE inhibition on diabetic nephropathy and normotensive type 1 diabetic patients. Kidney Int 2001;16:228-34.
42. Peterson JC, Adler S, Burkard JM, Greene T, et al., for the MDRD Study Group. Blood pressure control, proteinuria and the progression of renal disease. Ann Intern Med 1995;123:754-62.
43. Randomized placebo-controlled trial of effect of Ramipril on decline and glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group. Lancet 1997;349: 1857-63.
44. Ravid M, Savin H, Jutern I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:357-81.
45. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;20:1448-56.
46. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal diasease progression. Perspectives in clinical nephrology. Kidney Int 1997;51:2-15.
47. Remuzzi G. Sympathetic overactivity in hypertensive patients with chronic renal disease. N Engl J Med 1999;140:1360-1.
48. Ritz E, Rychlik I, Miltenberger-Miltenyi G. Optimizing antihypertensive therapy in patients with diabetic nephropathy. J Hypertens 1998;16:Suppl 7:S17-22.
49. Ruggenenti P. Perner A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathy with non-nephrotic proteinuria. Lancet 1999;354:359-64.
50. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. J Hypertens 2000;18:89-95
51. Russo D, Minutolo R, Pisani A, Esposito R. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.
52. Schwenger V, Ritz E. Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant 1998;13:3091-5.
53. Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993;153:973-80.
54. Stefanski A, Amann K, Ritz E. To prevent progression: ACE inhibitors, calcium antagonists or both? Nephrol Dial Transplant 1995;10:151-3.
55. Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects of calcium-channel blockers. Nephrol Dial Transplant 1997;12:2244-50.
56. The EUCLID Study Group. Randomized placebo-controlled trail of lisinopril normotensive patients with insulin-dependend diabetes and normoalbuminuria or microalbuminuna. Lancet 1997;349:1787-92.
57. The GISEN Group. Randomized placebo-controlled trial of effect of Kamipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997;349:1857-63.
58. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs WH, et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999;243:677-84.
59. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Br Med J 1998;317:703-12.
60. UK Prospectve Diabetes Study Group. Efficacy of atenolol and captopril in reducing the risk of macrovascular and microvascularconfications in typ 2 diabetes (ukPDS 39) BMJ 1998;317:713-20.
61. Wenzel UO, Helmchen U, Schoeppe W, Schwietzer G. Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension. Hypertension 1994;23:114-22.
62. World Health Organisation - International Society of Hypertension. Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments. J Hypertens 1998;16:127-37.